Table 4.

Trials evaluating tipifarnib as radiosensitizer, sorted by publication year

Author	Year	Agent	Dose	n	Radiation regimen	Results
Moyal et al. [31]	2007	Tipifarnib	1 week before, during and after RT, starting at 200 mg/day	13	60 Gy in 30 fractions	200 mg/day tipifarnib is well tolerated Median OS: 12 months
Lustig et al. [33]	2008	Tipifarnib	300 or 600 mg bid, 3 weeks on, 1 week off Three cycles	28	60 Gy in 30 fractions	Median OS: 234.5 days No measurable response or improvement
Nghiemphu et al. [34]	2011	Tipifarnib	5–9 days pre and during RT 3 weeks on, 1 week off	51	60 Gy in 30 fractions	MTD: 300 mg bid Tolerated with concurrent TMZ
		+ TMZ	75 mg/m2 (partially)
Ducassou et al. [35]	2013	Tipifarnib	100 mg bid 1 week before and during RT	27	60 Gy in 30 fractions	Median TTP: 23.1 weeks Median OS: 80.3 weeks

n = number of patients included (number of patients with glioblastoma in parentheses if multiple entities were included)